相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Microglia/macrophages express alternative proangiogenic factors depending on granulocyte content in human glioblastoma
Anne Blank et al.
JOURNAL OF PATHOLOGY (2021)
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
Lakshmi Nayak et al.
CLINICAL CANCER RESEARCH (2021)
What is the burden of proof for tumor mutational burden in gliomas?
Mustafa Khasraw et al.
NEURO-ONCOLOGY (2021)
Using viral vectors to deliver local immunotherapy to glioblastoma
Alexander F. Haddad et al.
NEUROSURGICAL FOCUS (2021)
Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas
Jiayi Zeng et al.
FRONTIERS IN IMMUNOLOGY (2021)
Experience With Ventriculoperitoneal and Lumboperitoneal Shunting for the Treatment of Idiopathic Intracranial Hypertension: A Single Institution Series
Ahmad Sweid et al.
OPERATIVE NEUROSURGERY (2021)
Safety and efficacy study of retifanlimab and epacadostat in combination with radiation and bevacizumab in patients with recurrent glioblastoma.
Jian Li Campian et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment
Wuzhen Chen et al.
BIOMARKER RESEARCH (2021)
Experience With Ventriculoperitoneal and Lumboperitoneal Shunting for the Treatment of Idiopathic Intracranial Hypertension: A Single Institution Series
Ahmad Sweid et al.
OPERATIVE NEUROSURGERY (2021)
Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma
Yu Long et al.
CANCER RESEARCH (2020)
Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance
Ankush Chandra et al.
CANCER RESEARCH (2020)
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
David A. Reardon et al.
CLINICAL CANCER RESEARCH (2020)
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)
Timothy F. Cloughesy et al.
NEURO-ONCOLOGY (2020)
Tumor mutational burden is associated with poor outcomes in diffuse glioma
Lihong Wang et al.
BMC CANCER (2020)
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma
Eudocia Q. Lee et al.
CANCER (2020)
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect
Rebecca C. Arend et al.
GYNECOLOGIC ONCOLOGY (2020)
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon et al.
JAMA ONCOLOGY (2020)
Mechanisms and therapeutic implications of hypermutation in gliomas
Mehdi Touat et al.
NATURE (2020)
Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
N. Garcia-Romero et al.
BMC MEDICINE (2020)
PD-L1 Expression in Glioblastoma, the Clinical and Prognostic Significance: A Systematic Literature Review and Meta-Analysis
Chengcheng Hao et al.
FRONTIERS IN ONCOLOGY (2020)
High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naive Patients with Diverse Cancers
Paul Riviere et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity
Won Suk Lee et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2020)
Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance
Leila Akkari et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor
Jaclyn J. Renfrow et al.
SCIENTIFIC REPORTS (2020)
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma A Randomized Clinical Trial
Timothy F. Cloughesy et al.
JAMA ONCOLOGY (2020)
TIM3 comes of age as an inhibitory receptor
Yochai Wolf et al.
NATURE REVIEWS IMMUNOLOGY (2020)
DGM1 may serve as a novel genetic biomarker of response to enzastaurin in glioblastoma.
Nicholas A. Butowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The Evolving Role of CD8+CD28- Immunosenescent T Cells in Cancer Immunology
Wei X. Huff et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Meningeal lymphatic vessels at the skull base drain cerebrospinal fluid
Ji Hoon Ahn et al.
NATURE (2019)
Phenotypic Evidence of T Cell Exhaustion and Senescence During Symptomatic Plasmodium falciparum Malaria
Augustina Frimpong et al.
FRONTIERS IN IMMUNOLOGY (2019)
LBA3IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
A-L Cheng et al.
ANNALS OF ONCOLOGY (2019)
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2019)
Pivotal Role of STAT3 in Shaping Glioblastoma Immune Microenvironment
Christina Piperi et al.
CELLS (2019)
VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers
Chang Gon Kim et al.
SCIENCE IMMUNOLOGY (2019)
Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment
Jessica L. F. Teh et al.
CLINICAL CANCER RESEARCH (2019)
Autocrine VEGF signalling on M2 macrophages regulates PD-L1 expression for immunomodulation of T cells
Yin-Siew Lai et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment
Amelie Griveau et al.
CANCER CELL (2018)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dal Fukurnura et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma
Mary Lou Affronti et al.
ONCOLOGIST (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
David A. Schaer et al.
CELL REPORTS (2018)
The Role of indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy
Lilla Hornyak et al.
FRONTIERS IN IMMUNOLOGY (2018)
Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma
Sarah Harris-Bookman et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Immunomodulation Mediated by Anti-angiogenic Therapy Improves CD8 T Cell Immunity Against Experimental Glioma
Courtney S. Malo et al.
FRONTIERS IN ONCOLOGY (2018)
Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
Jennifer E. Kim et al.
CLINICAL CANCER RESEARCH (2017)
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Biological Role and Therapeutic Targeting of TGF-β3 in Glioblastoma
Katharina Seystahl et al.
MOLECULAR CANCER THERAPEUTICS (2017)
ATIM-14. ALLIANCE A071101: A PHASE II RANDOMIZED TRIAL COMPARING THE EFFICACY OF HEAT SHOCK PROTEIN PEPTIDE COMPLEX-96 (HSPPC-96) VACCINE GIVEN WITH BEVACIZUMAB VERSUS BEVACIZUMAB ALONE IN THE TREATMENT OF SURGICALLY RESECTABLE RECURRENT GLIOBLASTOMA
Orin Bloch et al.
NEURO-ONCOLOGY (2017)
Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy
B. A. Castro et al.
ONCOGENE (2017)
Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation
Elizabeth Allen et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma
Song Xue et al.
ONCOTARGET (2017)
Celecoxib Down-Regulates the Hypoxia-Induced Expression of HIF-1α and VEGF Through the PI3K/AKT Pathway in Retinal Pigment Epithelial Cells
Yi-zhou Sun et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2017)
Expanded phase I study of intratumoral Ad-RTS-hIL-12 plus oral veledimex: Tolerability and survival in recurrent glioblastoma.
E. Antonio Chiocca et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment
Qianghu Wang et al.
CANCER CELL (2017)
GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance
Ruby Kuang et al.
JCI INSIGHT (2017)
Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma
Alexander Scholz et al.
EMBO MOLECULAR MEDICINE (2016)
Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model
Danielle N. Renner et al.
NEUROTHERAPEUTICS (2016)
Recent advances and future of immunotherapy for glioblastoma
Neha Kamran et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma
Edward Pan et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages
Teresa E. Peterson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival
Jonas Kloepper et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Role of interleukin-6 in cancer progression and therapeutic resistance
Neeraj Kumari et al.
TUMOR BIOLOGY (2016)
Molecular mechanisms of the effect of TGF-β1 on U87 human glioblastoma cells
Igor Bryukhovetskiy et al.
ONCOLOGY LETTERS (2016)
Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma
Sheng Han et al.
BMC CANCER (2015)
Targeting the tumor vasculature to enhance T cell activity
Evripidis Lanitis et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma
Elizabeth R. Gerstner et al.
NEURO-ONCOLOGY (2015)
A phase II study of the combination of BKM120 (buparlisib) and bevacizumab in patients with relapsed/refractory glioblastoma multiforme (GBM).
Kent C. Shih et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
HLA-G: An Immune Checkpoint Molecule
Edgardo D. Carosella et al.
ADVANCES IN IMMUNOLOGY, VOL 127 (2015)
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp et al.
LANCET ONCOLOGY (2014)
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Gregory T. Motz et al.
NATURE MEDICINE (2014)
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Anoop P. Patel et al.
SCIENCE (2014)
Transforming Growth Factor-Beta and Matrix Metalloproteinases: Functional Interactions in Tumor Stroma-Infiltrating Myeloid Cells
Jelena Krstic et al.
SCIENTIFIC WORLD JOURNAL (2014)
IL-10: Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity
Martin Oft
CANCER IMMUNOLOGY RESEARCH (2014)
Orchestration of angiogenesis by immune cells
Antonino Bruno et al.
FRONTIERS IN ONCOLOGY (2014)
β1 Integrin Targeting Potentiates Antiangiogenic Therapy and Inhibits the Growth of Bevacizumab-Resistant Glioblastoma
W. Shawn Carbonell et al.
CANCER RESEARCH (2013)
Glioblastoma Stem Cells Generate Vascular Pericytes to Support Vessel Function and Tumor Growth
Lin Cheng et al.
CELL (2013)
Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance
Arman Jahangiri et al.
CLINICAL CANCER RESEARCH (2013)
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial
Manfred Westphal et al.
LANCET ONCOLOGY (2013)
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma
Christine Lu-Emerson et al.
NEURO-ONCOLOGY (2013)
Advances in the study of HLA-restricted epitope vaccines
Lingxiao Zhao et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Improved survival time trends for glioblastoma using the SEER 17 population-based registries
Matthew Koshy et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy
Courtney A. Crane et al.
NEURO-ONCOLOGY (2012)
Endothelial Cells Create a Stem Cell Niche in Glioblastoma by Providing NOTCH Ligands That Nurture Self-Renewal of Cancer Stem-Like Cells
Thant S. Zhu et al.
CANCER RESEARCH (2011)
Effector T-Cell Infiltration Positively Impacts Survival of Glioblastoma Patients and Is Impaired by Tumor-Derived TGF-β
Jennifer Lohr et al.
CLINICAL CANCER RESEARCH (2011)
Bradykinin Promotes the Chemotactic Invasion of Primary Brain Tumors
Vedrana Montana et al.
JOURNAL OF NEUROSCIENCE (2011)
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Andrea Facciabene et al.
NATURE (2011)
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma
Nicholas Butowski et al.
NEURO-ONCOLOGY (2011)
The parallel lives of angiogenesis and immunosuppression: cancer and other tales
Gregory T. Motz et al.
NATURE REVIEWS IMMUNOLOGY (2011)
A Phase 1 Trial of ABT-510 Concurrent With Standard Chemoradiation for Patients With Newly Diagnosed Glioblastoma
Louis B. Nabors et al.
ARCHIVES OF NEUROLOGY (2010)
Molecular analysis of ex-vivo CD133+GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas
Juan L. Garcia et al.
BMC CANCER (2010)
A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2α
Sascha Seidel et al.
BRAIN (2010)
Perivascular Nitric Oxide Activates Notch Signaling and Promotes Stem-like Character in PDGF-Induced Glioma Cells
Nikki Charles et al.
CELL STEM CELL (2010)
Targeted knock down of CCL22 and CCL17 by siRNA during DC differentiation and maturation affects the recruitment of T subsets
Shijun Kang et al.
IMMUNOBIOLOGY (2010)
Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion
Xiaoyuan Huang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells
Lucia Ricci-Vitiani et al.
NATURE (2010)
Glioblastoma stem-like cells give rise to tumour endothelium
Rong Wang et al.
NATURE (2010)
A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas
Teri N. Kreisl et al.
NEURO-ONCOLOGY (2010)
Corticosteroid Use in Patients with Glioblastoma at First or Second Relapse Treated with Bevacizumab in the BRAIN Study
James J. Vredenburgh et al.
ONCOLOGIST (2010)
The bevacizumab experience in advanced renal cell carcinoma
Lauren Harshman
OncoTargets and Therapy (2010)
Imaging Glioma Cell Invasion In Vivo Reveals Mechanisms of Dissemination and Peritumoral Angiogenesis
Frank Winkler et al.
GLIA (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
CD36, a Scavenger Receptor Involved in Immunity, Metabolism, Angiogenesis, and Behavior
Roy L. Silverstein et al.
SCIENCE SIGNALING (2009)
Thalidomide inhibits epidermal growth factor-induced cell growth in mouse and human monocytic leukemia cells via Ras inactivation
Abu Shadat M. Noman et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Orchestrating the orchestrators: chemokines in control of T cell traffic
Shannon K. Bromley et al.
NATURE IMMUNOLOGY (2008)
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
Ronald J. Buckanovich et al.
NATURE MEDICINE (2008)
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults
Santosh Kesari et al.
NEURO-ONCOLOGY (2008)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
The role of myeloid cells in the promotion of tumour angiogenesis
Craig Murdoch et al.
NATURE REVIEWS CANCER (2008)
Integrins in angiogenesis and lymphangiogenesis
Christie J. Avraamides et al.
NATURE REVIEWS CANCER (2008)
Bv8 regulates myeloid-cell-dependent tumour angiogenesis
Farbod Shojaei et al.
NATURE (2007)
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Jayne M. Stommel et al.
SCIENCE (2007)
Molecular signature of CD8+ T cell exhaustion during chronic viral infection
E. John Wherry et al.
IMMUNITY (2007)
Historical controls for phase II surgically based trials requiring gross total resection of glioblastoma multiforme
Nicholas Butowski et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Role of tumor endothelium in CD4+CD25+ regulatory T cell infiltration of human pancreatic carcinoma
Daniel Nummer et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Angiogenesis in brain tumours
Rakesh K. Jain et al.
NATURE REVIEWS NEUROSCIENCE (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation
Victor A. Levin et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.
PE Fecci et al.
CANCER RESEARCH (2006)
Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain
D Zagzag et al.
LABORATORY INVESTIGATION (2005)
Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation
MM Dikov et al.
JOURNAL OF IMMUNOLOGY (2005)
Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer
TJ Curiel et al.
CANCER RESEARCH (2004)
Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells
JM Brenchley et al.
BLOOD (2003)
Endothelial expression of PD-L1 and PD-L2 down-regulates CD8(+) T cell activation and cytolysis
N Rodig et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Balancing the activation state of the endothelium via two distinct TGF-β type I receptors
MJ Goumans et al.
EMBO JOURNAL (2002)
Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism
VV Didenko et al.
JOURNAL OF NEUROSURGERY (2002)
Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta
W Wick et al.
JOURNAL OF NEURO-ONCOLOGY (2001)
VEGF as a Mediator of tumor-associated immunodeficiency
JE Ohm et al.
IMMUNOLOGIC RESEARCH (2001)
A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme
NG Rainov
HUMAN GENE THERAPY (2000)
分享论文
